Should Johnson & Johnson Split Up?

Brenton Flynn, David Williamson, and Max Macaluso, Ph.D., The Motley Fool
Updated

Our health care roundtable gathers the Motley Fool's top health care analysts to discuss the sector's biggest stories in a free flowing and highly opinionated format.

In this portion of the discussion, the Fool's health care team tackles the recent big pharma trend of spinning off whole divisions, like AbbottLabs' plans for pharmaceutical-focused AbbVie. Would conglomerate Johnson & Johnson benefit from shedding a little extra weight and spinning off a company or two?

None


The article Should Johnson & Johnson Split Up? originally appeared on Fool.com.

Brenton Flynn has no positions in the stocks mentioned above. David Williamson owns shares of Pfizer. Follow him on Twitter @MotleyDavid. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement